Wie hoch ist der Preis für Thalia Therapeutics Plc (THAT)

Preis für Thalia Therapeutics Plc (THAT) ist $0.00918474

Wie hoch ist die Marktkapitalisierung für Thalia Therapeutics Plc (THAT)

Marktkapitalisierung für Thalia Therapeutics Plc (THAT) ist $76.44K

Thalia Therapeutics Plc (THAT) EPS

Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.

Jahr	EPS	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

EPS

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	EPS	EPS-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-	BE

Unternehmen

EPS

EPS-Differenz

Land